PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $11,583 | -31.9% | 300 | 0.0% | 0.00% | -20.0% |
| Q2 2022 | $17,000 | -26.1% | 300 | 0.0% | 0.01% | 0.0% |
| Q1 2022 | $23,000 | +27.8% | 300 | 0.0% | 0.01% | +25.0% |
| Q4 2021 | $18,000 | +5.9% | 300 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $17,000 | -5.6% | 300 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $18,000 | -14.3% | 300 | 0.0% | 0.00% | -20.0% |
| Q1 2021 | $21,000 | +16.7% | 300 | 0.0% | 0.01% | +25.0% |
| Q4 2020 | $18,000 | 0.0% | 300 | 0.0% | 0.00% | -20.0% |
| Q3 2020 | $18,000 | +12.5% | 300 | 0.0% | 0.01% | 0.0% |
| Q2 2020 | $16,000 | +60.0% | 300 | 0.0% | 0.01% | 0.0% |
| Q1 2020 | $10,000 | -28.6% | 300 | 0.0% | 0.01% | -16.7% |
| Q4 2019 | $14,000 | +27.3% | 300 | 0.0% | 0.01% | +20.0% |
| Q3 2019 | $11,000 | -15.4% | 300 | 0.0% | 0.01% | -28.6% |
| Q2 2019 | $13,000 | +18.2% | 300 | 0.0% | 0.01% | +16.7% |
| Q1 2019 | $11,000 | -15.4% | 300 | 0.0% | 0.01% | -25.0% |
| Q4 2018 | $13,000 | – | 300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |